IMT-009 is under clinical development by Immunitas Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMT-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMT-009 is under development for the treatment solid tumors and hematological malignancies including squamous or non-squamous non-small cell lung cancer, head and neck squamous cell carcinoma, triple negative breast cancer, cutaneous squamous cell carcinoma, hormone receptor positive breast cancer, small bowel carcinoma, esophageal cancer, colorectal cancer, diffuse large b cell lymphoma, Hodgkin lymphoma, t cell lymphoma. It is administered through intravenous route. IMT-009, acts by targeting CD161. The therapeutic candidate is being developed based on single cell genomics platform.
Immunitas Therapeutics overview
Immunitas Therapeutics discovers and develops targeted treatments for various oncology indications. The company is investigating antibodies and biomarkers to treat cancer. It utilizes a single cell genomics platform to develop drugs by analyzing the biology of immune cells in human tumors. The company’s funding partners include Alexandria Real Estate Equities Inc, Evotec AG, Longwood Fund and M Ventures, among others. Immunitas Therapeutics is headquartered in Waltham, Massachusetts, the US.
For a complete picture of IMT-009’s drug-specific PTSR and LoA scores, buy the report here.